- Home
- ROIV vs HIG Comparison
ROIV vs HIG Comparison
Compare ROIV & HIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROIV | HIG |
|---|---|---|
| Founded | 2014 | 1810 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 33.7B |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ROIV | HIG |
|---|---|---|
| Price | $35.43 | $129.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 23 |
| Target Price | $48.08 | ★ $148.00 |
| AVG Volume (30 Days) | ★ 6.0M | 1.5M |
| Earning Date | 11-09-2026 | 10-26-2026 |
| Dividend Yield | N/A | ★ 1.85% |
| EPS Growth | N/A | ★ 28.70 |
| EPS | N/A | ★ 7.71 |
| Revenue | $8,260,000.00 | ★ $28,368,000,000.00 |
| Revenue This Year | $530.75 | $2.07 |
| Revenue Next Year | $685.92 | $3.35 |
| P/E Ratio | ★ N/A | $16.79 |
| Revenue Growth | N/A | ★ 6.91 |
| 52 Week Low | $15.99 | $120.33 |
| 52 Week High | $42.50 | $146.07 |
Technical Indicators
Market Signals| Indicator | ROIV | HIG |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | 47.36 |
| Support Level | $33.15 | $126.87 |
| Resistance Level | $35.70 | $141.03 |
| Average True Range (ATR) | 1.14 | 2.32 |
| MACD | -0.34 | 0.60 |
| Stochastic Oscillator | 35.90 | 85.94 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About HIG Hartford Financial Services Group Inc. (The)
The Hartford Insurance Group Inc. provides property and casualty insurance, group benefits, and mutual funds. The company is widely recognized for its service excellence, sustainability practices, trust, and integrity. The Company currently conducts business principally in five reportable segments, including Business Insurance, Personal Insurance, Property & Casualty Other Operations, Employee Benefits, and Hartford Funds, as well as a Corporate category. The company generates a majority of its revenue from Business Insurance.